Proud to contribute EAVI2020 to research for a cure of #HIV @worldaidsday

Congratulations to our collaborator @georg_e_winter CeMM for this distinction!

check the new website Vienna BioCenter

How is life on the cell surface? Many models and diagrams show the cell surface as stiff and unmovable barrier between cells and the outside. But imagine cell membranes are an extremely thin fluid layer of a fatty substance (lipids), which forms a barrier. #biolution #cell

Metallhaltige #Chemotherapien verstärken Wirkung der #Immuntherapie bei #Krebs meduniwien.ac.at/web/ueber-uns/…

We had an exciting 14 years in a time cancer research saw fantastic developments. It was great to have the opportunitiy to contribute with the support of so many collaborators and partners. Thank you all for your support. But now it is time to say goodbye!

Everyone @LBI_CR wishes our followers a wonderful holiday season and a succesful New Year. The instute will be integrated into our partners MedUni Wien and Vetmeduni, thus as of 2018 the institute comes to its scheduled end.

Apply now for the #CeMMPostdocProgram in Vienna, that includes two interesting potential projects in the group of Kaan Boztug, one focusing on Precision pediatric oncology and the other on Organoid-omics.

This old Twitter account is now taken over by JAKSTAT-Target consortium project which aims to create individualized therapy options and strategies to predict treatment response for patients with mature T-cell leukemias/lymphomas

JAKSTAT-TARGET is a collaboration between PIs Satu Mustjoki HRUH hematology, Patrick Gunning Gunning Group, Marco Herling from Universität zu Köln, Tero Aittokallio lab from FIMM HelsinkiUni, Benjamin Haibe-Kains lab from University Health Network, and Heidi Neubauer lab from Vetmeduni and funded by #erapermed

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine nature.com/articles/s4137…

New version of #SynergyFinder, a widely used web-tool for interactive analysis and visualization of drug combination screening data, now available. Updated tool published by Group Aittokallio FIMM HelsinkiUni HiLIFE_Helsinki in @NAR_Open. #datascience helsinki.fi/en/news/life-s…

News from JAKSTAT-Target: New version of the SynergyFinder webtool available! New features support higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns helsinki.fi/en/news/life-s…

New insights regarding future therapies for human immunological diseases: vetmeduni.ac.at/en/infoservice…

New publication from the project! The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5: jci.org/articles/view/…

Stay up to date on more exciting research progress from this multidisciplinary initiative to advance new #JAKSTAT-targeted therapeutics for T-cell leukemias/lymphomas at the @JAKSTATtarget consortium website: jak-stat.org

Presenting some publications from work conducted by the JAK-STAT Target consortium Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine by Pützer et al. 2020 pubmed.ncbi.nlm.nih.gov/32099034/

Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature by Kelkka et al. 2020 from HRUH hematology Translational Immunology Research Program (TRIMM) frontiersin.org/articles/10.33…

Ianevski et al. 2021, from the Aittokallio group at FIMM HelsinkiUni Patient-tailored design for selective co-inhibition of leukemic cell subpopulations advances.sciencemag.org/content/7/8/ea…

Check out our submission for the ERA-Net PerMed video competition summarizing 3 years of work with the @JAKSTATtarget Consortium! Great video editing by our MSc student Bilal Saqib. The winner will be decided by Youtube likes, so please like and share! youtu.be/DIDkmqQg-Do